PT - JOURNAL ARTICLE AU - Cotugno, Nicola AU - Pighi, Chiara AU - Morrocchi, Elena AU - Ruggiero, Alessandra AU - Amodio, Donato AU - Medri, Chiara AU - Colagrossi, Luna AU - Russo, Cristina AU - Cesare, Silvia Di AU - Santilli, Veronica AU - Manno, Emma Concetta AU - Zangari, Paola AU - Giancotta, Carmela AU - Bernardi, Stefania AU - Nicolosi, Luciana AU - Degli Atti, Marta Ciofi AU - Raponi, Massimiliano AU - Zaffina, Salvatore AU - Alfieri, Sara AU - Kirk, Richard AU - Perno, Carlo Federico AU - Rossi, Paolo AU - , AU - Amodeo, Antonino AU - Palma, Paolo TI - HUMORAL AND CELLULAR IMMUNOGENICITY and SAFETY UP TO 4 MONTHS AFTER VACCINATION WITH BNT162B2 mRNA COVID-19 VACCINE IN HEART AND LUNG TRANSPLANTED YOUNG ADULTS AID - 10.1101/2021.09.20.21263836 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.20.21263836 4099 - http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263836.short 4100 - http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263836.full AB - Background Immunizations among vulnerable population, including solid organ transplant recipients (SOT), present suboptimal responses at vaccination and over time. We investigated safety and immunogenicity of the BNT162B2 mRNA COVID-19 vaccine in 34 SOT young adults as compared to 36 healthy controls (HC).Methods immunogenicity was measured through the analysis of anti SARS-CoV2 IgG Antibodies and antigen specific CD4 T cells (CD40L+), detected by flow cytometry before vaccination, 21 days after priming (T21), 7 days after booster dose (T28) and 2-4 months after priming (T120). Baseline T and B cell immune phenotype was deeply investigated. The safety profile was investigated by close monitoring and self-reported diary.Results Anti-S and anti-Trimeric Ab responses were significantly lower in SOT vs HC at T21 (p<0.0001) and at T28 (p<0.0001). Ten out of 34 SOT (29%) at T28 and 3 out of 33 (9%) at T120 had undetectable SARS-CoV-2 IgG. The analysis of SARS-CoV-2 specific CD4 T cells showed lower CD40L expression after in vitro stimulation in SOT compared to HC. Lower frequencies of memory B cells were found in patients not responding to vaccination. Lack of seroconversion was higher in patients treated with mycophenolate (p=0.0005). The vaccination was safe and well tolerated. Only short-term adverse events, were reported and no hospitalization or graft rejection were observed after vaccinations.Conclusions These data show that SOT have a suboptimal immune response following mRNA vaccinations as compared to HC. Alternative strategies should be investigated to improve the immunization against SARS-CoV-2 in these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible by support from Bambino Gesu Children Hospital through Italian Ministry of Health, ricerca corrente 2020 to NC and ricerca corrente 2019 to PP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Bambino Gesu' Children's Hospital Ethical CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for the submitted paper are available upon request to the Corresponding Author.Anti-HLAanti human leukocyte antigenCOVID19coronavirus disease 2019EDTAEthylenediamine tetraacetic acidHChealthy controlsIFNinterferonIL2interleukin 2mRNAmessenger Ribonucleic AcidPBMCsPeripheral Blood Mononuclear CellsSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus-2SOTSolid Organ Transplant Recipients